

### **Company Update**

**December 4, 2018** 

₹ 458

# Rating matrix Rating : Hold Target : ₹ 460 Target Period : 12-15 months Potential Upside : 0%

What's Changed?	
Target	Changed from ₹ 630 to ₹ 460
EPS FY19E	Unchanged
EPS FY20E	Unchanged
Rating	Changed from Buy to Hold

Key Financials				
(₹ Crore)	FY17	FY18	FY19E	FY20E
Net Sales	31578.4	26489.5	29336.9	33066.7
EBITDA	10089.3	5608.1	5983.6	7712.1
Adj. Profit	6964.4	3112.1	3520.0	5073.9
Adj. EPS (₹)	29.0	13.0	14.7	21.1

Valuation summary	,			
	FY17	FY16	FY19E	FY20E
PE (x)	15.8	22.2	47.7	21.7
EV to EBITDA (x)	10.3	11.9	17.3	13.1
Price to book (x)	3.0	3.5	2.7	2.5
RoNW (%)	19.0	18.0	8.8	11.5
RoCE (%)	20.3	18.6	10.2	13.3

Stock data	
Particular	Amount
Market Capitalisation	₹ 109946 crore
Debt (FY18)	₹ 9752 crore
Cash & Cash Equivalents (FY18)	₹ 21244 crore
EV (₹ Cr)	₹ 98454 crore
52 week H/L (₹)	679/435
Equity capital	₹ 239.9 crore
Face value	₹1



#### Research Analyst

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Mitesh Shah mitesh.sha@icicisecurities.com

## Sun Pharmaceuticals (SUNPHA)

## Management tries to alleviate concerns...

The management of Sun Pharma conducted a conference call to address apprehension among investors after a recent publication by a brokerage regarding so called corporate governance issues and a complaint filed by a whistleblower with Sebi highlighting so called wrongdoings in the company. While the first issue was addressed with a case by case analysis, question marks remain over the whistleblower's complaint for want of management action plan as the management awaits Sebi correspondence. Following are the extracts of management explanations-

- Subsidiary auditors (Valia and Timbadia) were allegedly involved in stock price rigging – 20 years old matter. The firm audits some of the smaller subsidiaries (account for 0.6% of revenues in FY18)
- Sudhir Valia owned Lakshdeep Investments It is a non-promoter company and has no material impact
- Small firm Jermyn Capital appointed as manager for FCCBs 14-year old matter. JP Morgan Chase was lead and sole book runner while Jermyn Capital was just a co-manager
- Loan to four individuals without security: a very small loan was given
   20 years ago while the amount was already recovered
- Insider trading involvement at the time of Ranbaxy acquisition -There was a technical issue as the company failed to notify about
  trading window closure on a holiday. Hence, Sebi fined the company
  and was duly settled
- Bought share of Natco Pharma from Orange Mauritius: The promoter bought Natco Pharma shares in personal capacity and provided appropriate disclosure at the time of purchase
- Domestic business via related party (Aditya Medisales (AML): It became a related party from FY18 due to consolidation of shareholding of investment companies, held by promoters. If required, the management is open to buying the distributor and discontinuing current arrangement to alleviate the concern
- Loans to employees/others: Total ₹ 2240 crore was invested in other pharma businesses. However, details were not provided
- Suraksha Realty The company did not provide any guarantee
- Lower tax rate Due to tax efficient measures and plants being in tax free zone
- Whistleblower's complaint: No query has come from Sebi as yet

#### "Corporate governance" overhang likely to overshadow fundamentals

While the first issue was addressed with a case by case analysis, question marks remain over the whistleblower's complaint for want of management action plan as the management awaits Sebi correspondence. Similarly, concerns regarding issues related to transactions with AML (related party distributor) and Loans and Advances to others (which witnessed a sharp spurt in FY18) are unlikely to settle down easily. These so-called CG issues are likely to weigh on the stock in the near to medium term, especially in a period where these issues are extensively scrutinised by investors. We reduce our multiple to 20x (from 28x). Hence, we arrive at our new target price of ₹ 460 based on 20x FY20E EPS of ₹ 21.1 and ₹ 38 NPV for Ilumnya.



# **Financial summary**

Profit and loss statement				₹ Crore
(Year-end March)	FY17	FY18	FY19E	FY20E
Revenues	31,578.4	26,489.5	29,336.9	33,066.7
Growth (%)	10.6	-16.1	10.7	12.7
Raw Material Expenses	8,130.7	7,424.7	8,265.3	8,928.0
Employee Expenses	4,902.3	5,367.1	5,841.6	6,506.6
Other Expenditure	8,456.1	8,089.6	9,246.4	9,920.0
Total Operating Expenditure	21,489.2	20,881.3	23,353.3	25,354.6
EBITDA	10,089.3	5,608.1	5,983.6	7,712.1
Growth (%)	15.6	-44.4	6.7	28.9
Depreciation	1,264.8	1,499.8	1,684.7	1,424.5
Interest	399.8	517.6	519.5	444.4
Other Income	623.2	838.8	1,030.3	1,126.2
PBT	9,047.9	4,429.5	4,809.7	6,969.3
Less: Exceptional Items	0.0	950.5	1,214.4	0.0
Total Tax	1,211.6	845.2	780.5	1,254.5
PAT	6,964.4	2,161.6	2,305.6	5,073.9
Minority Interest	881.9	446.8	504.6	633.4
Adjusted PAT	6,964.4	3,112.1	3,520.0	5,073.9
Growth (%)	23.2	-55.3	13.1	44.1
EPS (Adjusted)	29.0	13.0	14.7	21.1

Source: Company, ICICI Direct Research

Balance sheet				₹ Crore
(Year-end March)	FY17	FY18	FY19E	FY20E
Equity Capital	239.9	239.9	239.9	239.9
Reserve and Surplus	36,399.7	37,860.6	39,772.1	43,978.7
Total Shareholders funds	36,639.7	38,100.6	40,012.0	44,218.7
Total Debt	9,827.8	9,751.8	9,385.3	8,385.3
Deferred Tax Liability	461.9	219.0	234.3	250.7
Minority Interest	3,790.9	3,884.2	4,388.7	5,022.1
Other LT Liabitlies & LT Provision	1,341.8	462.7	495.1	529.8
Total Liabilities	52,062.1	52,418.2	54,515.4	58,406.5
Gross Block - Fixed Assets	22,154.5	21,342.1	22,542.1	23,742.1
Accumulated Depreciation	10,015.5	8,096.2	9,780.9	11,205.4
Net Block	12,138.9	13,245.9	12,761.2	12,536.7
Capital WIP	2,801.4	2,465.2	2,465.2	2,465.2
Total Fixed Assets	14,940.3	15,711.1	15,226.4	15,001.8
Investments	1,191.9	7,142.9	9,448.3	11,753.7
Deferred tax assets	5,617.8	2,193.8	2,347.3	2,511.7
Goodwill on Consolidation	5,536.2	5,606.7	5,606.7	5,606.7
LT Loans & Advances & Assets	1,401.2	6,103.1	6,530.3	6,987.4
Cash	15,140.8	9,929.4	10,672.4	11,010.9
Debtors	7,202.6	7,815.3	6,348.6	7,154.5
Loans and Advances	1,019.1	91.4	97.8	104.7
Inventory	6,832.8	6,880.7	6,398.9	7,211.1
Other current assets	2,527.4	2,828.5	3,026.5	3,238.3
Total Current Assets	32,722.8	27,545.3	26,544.3	28,719.5
Creditors	4,395.4	4,766.2	3,571.1	4,024.4
Provisions & other current liability	4,952.8	7,118.4	7,616.7	8,149.9
Total Current Liabilities	9,348.2	11,884.6	11,187.8	12,174.3
Net Current Assets	23,374.6	15,660.7	15,356.5	16,545.2
Application of Funds	52,062.1	52,418.2	54,515.4	58,406.5

Source: Company, ICICI Direct Research

Cash flow statement				₹ Crore
(Year-end March)	FY17	FY18	FY19E	FY20E
Profit/(Loss) after taxation	6964.4	2737.2	2305.6	5073.9
Depreciation	1264.8	1499.8	1684.7	1424.5
(Inc)/Dec in Current Assets	-1421.9	-893.3	1744.0	-1836.8
(Inc)/Dec in Current Liabilities	453.3	681.0	-668.5	1016.7
Others	-178.3	-117.6	519.5	444.4
CF from operation	7082.2	3907.2	5585.4	6122.9
Purchase of Fixed Assets	-3590.4	-1894.3	-1200.0	-1200.0
(Inc)/Dec in Investments	-843.7	-5594.3	-2305.4	-2305.4
Others	7044.9	-90.8	-56.8	32.7
CF from Investing Activities	2610.8	-7579.4	-3562.2	-3472.7
Inc / (Dec) in Loan Funds	837.1	-575.0	-366.5	-1000.0
Inc / (Dec) in Equity Capital	-2730.8	0.0	0.0	0.0
Dividend and dividend tax	-289.7	-960.5	-394.1	-867.3
Other Financial Activities	-400.5	-3.8	-519.5	-444.4
CF from Financing Activities	-2583.9	-1539.3	-1280.1	-2311.7
Cash generation during the year	7109.2	-5211.5	743.1	338.5
Op bal Cash & Cash equivalents	8031.7	15140.8	9929.4	10672.4
Closing Cash/ Cash Equivalent	15140.8	9929.4	10672.4	11010.9
Free Cash Flow	3491.8	2012.9	4385.4	4922.9

Source: Company, ICICI Direct Research

Key ratios				
(Year-end March)	FY17	FY18	FY19E	FY20E
Per share data (₹)				
Adjusted EPS	29.0	13.0	14.7	21.1
BV per share	152.7	158.8	166.8	184.3
Dividend per share	1.2	2.0	1.6	3.6
Cash Per Share	63.1	41.4	44.5	45.9
Operating Ratios (%)				
Gross Margin	74.3	72.0	71.8	73.0
EBITDA Margin	31.9	21.2	20.4	23.3
PAT Margin	22.1	11.7	12.0	15.3
Inventory days	79.0	94.8	79.6	79.6
Debtor days	83.3	107.7	79.0	79.0
Creditor days	50.8	65.7	44.4	44.4
Asset Turnover	0.7	0.5	0.6	0.6
EBITDA Conversion rate	70.2	69.7	93.3	79.4
Return Ratios (%)				
RoE	19.0	8.2	8.8	11.5
RoCE	20.3	9.8	10.2	13.3
RoIC	31.2	12.2	12.7	17.3
Valuation Ratios (x)				
P/E	15.8	50.9	47.7	21.7
EV / EBITDA	10.3	18.8	17.3	13.1
EV / Net Sales	3.3	4.0	3.5	3.1
Market Cap / Sales	3.5	4.2	3.7	3.3
Price to Book Value	3.0	2.9	2.7	2.5
Solvency Ratios				
Debt / EBITDA	1.0	1.7	1.6	1.1
Debt / Equity	0.3	0.3	0.2	0.2
Current Ratio	1.9	1.5	1.4	1.5

Source: Company, ICICI Direct Research



#### RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock.

Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction;

Buy: >10%/15% for large caps/midcaps, respectively;

Hold: Up to  $\pm$ -10%; Sell: -10% or more;



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com



#### ANALYST CERTIFICATION

We /l, Siddhant Khandekar CA-INTER, Mitesh Shah MS (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, *inter alia*, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a Sebi registered Research Analyst with Sebi Registration Number – INH000000990. ICICI Securities Limited Sebi Registration is INZ000183631 for stock broker. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

It is confirmed that Siddhant Khandekar CA-INTER, Mitesh Shah MS (Finance) Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

It is confirmed that Siddhant Khandekar CA-INTER, Mitesh Shah MS (Finance) Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.